Where Absci Stands With Analysts
Over the past 3 months, 4 analysts have published their opinion on Absci (NASDAQ:ABSI) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
B of A Securities Downgrades Absci to Underperform, Lowers Price Target to $10
B of A Securities analyst Michael Ryskin downgrades Absci (NASDAQ:ABSI) from Neutral to Underperform and lowers the price target from $17 to $10.
75 Biggest Movers From Yesterday
Gainers
Society Pass Incorporated (NASDAQ: SOPA) surged 436.7% to settle at $48.30 on Tuesday after the company priced its IPO at $9 per share.
Absci Earlier Reported Q3 EPS $(0.33) Misses $(0.18) Estimate, Sales $1.54M Miss $2.01M Estimate
Absci (NASDAQ:ABSI) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.18) by 83.33 percent. The company reported quarterly sales of $1.54 million which missed the analyst
58 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Dover Motorsports, Inc. (NYSE: DVD) shares climbed 60.3% to $3.59 after Speedway Motorsports announced it will acquire the company for $3.61 per share in cash.
Earnings Scheduled For November 9, 2021
Companies Reporting Before The Bell
• Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter.
• KT (NYSE:KT) is projected to report earnings for its third quarter.
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 11)